Target intelligence / Profile preview

Folate receptor beta (FR-beta) (FOLR2)

Target
FOLR2
Molecular classification
Receptor
01

Overview

Folate receptor beta (FR-beta), encoded by the FOLR2 gene, is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein that binds folic acid and its reduced derivatives with high affinity. Unlike folate receptor alpha (FR-alpha), which is primarily expressed on epithelial cells, FOLR2 is selectively expressed on cells of the myeloid lineage, particularly activated macrophages, monocytes, and malignant myeloid cells. In the tumor microenvironment, FOLR2 is highly upregulated on immunosuppressive M2-polarized tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), where it contributes to tumor progression, immune evasion, and metastasis. It is also highly expressed on leukemic blasts in acute myeloid leukemia (AML) and on activated macrophages in chronic inflammatory and autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and myocarditis.

Due to its restricted expression profile, FOLR2 represents an attractive therapeutic target for both direct cancer therapy and macrophage-reprogramming immunotherapies. Therapeutic strategies targeting FOLR2 include monoclonal antibodies (e.g., m909) that induce antibody-dependent cell-mediated cytotoxicity (ADCC), folate-drug conjugates (e.g., the folate-aminopterin conjugate EC2319) that deliver cytotoxic payloads directly to activated macrophages, and CAR-T cell therapies. Additionally, FOLR2 is utilized as a target for non-invasive PET imaging and fluorescence-guided surgery using folate-conjugated tracers and dyes like pafolacianine.

Other names
Folate receptor 2Folate receptor, fetal/placentalPlacental folate-binding proteinFBPFBP/PL-1FR-BETAFR-P3BETA-HFR
02

Mechanism of action

Antibody-dependent cell-mediated cytotoxicity (ADCC), folate-receptor-mediated endocytosis of drug conjugates, and competitive inhibition of folate uptake.

03

Biological functions

Immune responseCell proliferationOther
04

Disease associations

CancerInflammationOther
05

Safety considerations

Potential on-target off-tumor toxicity in myeloid-rich tissues (spleen, bone marrow, thymus)Immunosuppression due to depletion of regulatory macrophagesInfusion-related reactionsCytokine release syndrome (CRS) risk
06

Interacting drugs

EC2319

6 more in the full profile.

07

Biomarkers

FOLR2 expressionFolate receptor beta expressionFR-beta-positive macrophages[18F]fluoro-PEG-folate uptake[68Ga]FOL uptake

Beyond the preview

Go deeper on Folate receptor beta (FR-beta) (FOLR2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Folate receptor beta (FR-beta) (FOLR2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call